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specific antigens (Fehling et al., 1994; Van Kaer et al.,The Salk Institute for Biological Studies
1994; Yewdell et al., 1994; Zhou et al., 1994; CerundoloSan Diego, California 92186-5800
et al., 1995). Mice that lack LMP2 present an influenza‡Public Health Research Institute
A epitope less efficiently than wild-type controls, indi-455 First Avenue
cating a role for LMP2 in the generation of specializedNew York, New York 10016
peptides during influenza infection (Van Kaer et al.,§Department de Microbiologia
1994). LMP72/2 mice have reduced class I surface ex-Universidade Federal de Minas Gerias
pression and present the endogenous HY antigen ineffi-Belo Horizonte
ciently (Fehling et al., 1994). A recent study has linkedMG CEP 31270-901
the pattern of cleavage by proteasomes to the efficiencyBrazil
of presentation by class I molecules (Niedermann et al.,
1995). Therefore, association of LMP2 and LMP7 with
the proteasome is functionally important for antigen pro-Summary
cessing and presentation of specific antigens by MHC
class I molecules.The TAP1 and LMP2 genes are central for class I MHC
TAP1 and TAP2 form a heterodimer that resides in thefunction and share a common promoter. Here, we ana-
endoplasmic reticulum (ER) and transports degradedlyze the molecular mechanism of IFNg up-regulation
peptides into the ER lumen (Neefjes et al., 1993; Shep-of TAP1 and LMP2. In vivo footprinting indicates IFNg
herd et al., 1993). For the class I MHC molecule to beup-regulates protein–DNA contacts at an IRF-E that
correctly assembled and transported to the cell surface,is essential for the up-regulation of TAP1 and LMP2
the class I heavy chain must bind peptide and b2-micro-by IFNg. Gel shift analysis indicates that this site binds
globulin (b2m) in the ER lumen (Machold et al., 1995;IRF-1. The expression of TAP1 and LMP2 are both
Ljunggren et al., 1990; Townsend et al., 1989). Mutantgreatly reduced in IRF-1-deficient mice. Surface class
cells lacking TAP1 or TAP2 lack peptide in the ER andI MHC as well as CD81 T cells are reduced in IRF-12/2
have no functional class I MHC molecules on the cellmice. The role of IRF-1 in the regulation of TAP1 and
surface (Monaco et al., 1990; Trowsdale et al., 1990;LMP2 suggests a mechanism for the antiviral proper-
Spies et al., 1990). Recent studies have found that theties of IRF-1 and the unexpected deficiency of CD81
class I MHC molecule physically interacts with the TAPT cells observed in IRF-12/2 mice.
heterodimer and imply that the TAP complex may also
serve a chaperone role by inducing a conformational
Introduction
change in the class I molecule (Day et al., 1995; Andro-
lewicz et al., 1994; Ortmann et al., 1994). TAP12/2 mice
Class I major histocompatibility complex (MHC) mole-
have reduced levels of class I and, as a result, have a
cules are essential for education of CD81 T cells in the
severe deficiency in CD81 T cells (Van Kaer et al., 1992).
thymus and for presentation of degraded antigenic pep-
IFNg, a cytokine secreted by T lymphocytes and natu-
tide to the CD81 T cell population (van Bleek and Nath- ral killercells, up-regulates a numberof immune system–
enson, 1992; Zinkernagel and Doherty, 1979). The pre- related genes, including class I MHC, TAP1/2, and
sentation of peptides by class I MHC molecules is LMP2/7, and mediates antiviral, antipathogenic, and
dependent on the products of a number of genes, some antiproliferative effects (Kerr and Stark, 1992; Stark
of which are nestled among class II MHC genes, namely and Kerr, 1992; Trowsdale et al., 1990; Farrar and
low molecular mass polypeptide 2 (LMP2), LMP7, trans- Schreiber, 1993; Vilcek and Olliveira, 1994; Murray,
porter associated with antigen presentation 1 (TAP1), 1994). Mice lacking either the IFNg receptor or the IFNg
and TAP2. Peptides presented in the class I cleft are molecule display decreased immune functions (Dalton
primarily from endogenous sources and are degraded et al., 1993) and are more susceptible to a variety of
in the cytoplasm, most likely by the 20S proteasome infections (Cooper et al.,1993; Kamijoet al., 1993; Huang
complex (Tanaka, 1994; Gaczynska et al., 1994; Micha- et al., 1993; Muller et al., 1994). The IFN-regulatory factor
lek et al., 1993; Townsend et al., 1988). Two proteasome 1 protein (IRF-1, also called IFN-stimulated gene factor
subunits, LMP2 and LMP7, associate with the 20S com- 2 [ISGF-2]) is up-regulated by IFNg and was originally
plex following induction by interferon-g (IFNg) (Belich identified as a protein that binds cis-acting DNA ele-
ments in the IFNb promoter (Pine et al., 1990; Miyamoto
et al., 1988; Fujita et al., 1988) and the IFN-stimulated‖ The first two authors contributed equally to this work.
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response element (ISRE) of IFNa/b-stimulated genes In this paper, we describe the initial molecular charac-
(Parrington et al., 1993; Levy et al., 1988). IRF-1 is main- terization of TAP1 and LMP2 gene up-regulation by
tained at a low constitutive level, and protein synthesis IFNg. We demonstrate that IRF-1 binds an IRF-Eelement
is required for its up-regulation (Levy et al., 1988). The within the TAP1/LMP2 promoter. Binding at this site is
IRF-1 gene is responsive to a number of hormones and induced by IFNg treatment and is essential for IFNg-
cytokines in addition to IFNg, including IFNa, IL-1, IL-6, induced expression of both TAP1 and LMP2. Further-
TNFa, leukemia inhibitory factor, and prolactin (Abdol- more, in primary and secondary lymphoid tissues from
lahi et al., 1991; Yu-Lee et al., 1990; Fujita et al., 1989). IRF-1-deficient mice, TAP1 and LMP2 expression is
The IRF-1 protein binds to a cis-acting element called drastically decreased. The regulation of TAP1 and LMP2
the IRF enhancer (IRF-E) (Tanaka et al., 1993; Harada by IRF-1 suggests a mechanism by which IRF-1 can
et al., 1989). regulate CD81 T cell development and exhibit antiviral
Studies using mice deficient in the IRF-1 gene have effects.
implicated IRF-1 in the regulation of the Gbp gene (Ki-
mura et al., 1994; Briken et al., 1995), the inducible nitric
oxide synthase genes (iNOS) (Kamijo et al., 1994; Reis Results
et al., 1994), and the Ice gene (Tamura et al., 1995).
Evidence from experiments using cultured cells also In Vivo Protein–DNA Interactions over the IRF-E
suggests that IRF-1 plays a role in the regulation of the Site Are Induced by IFNg
IFNb gene (Watanabe et al., 1991; Harada et al., 1990), TAP1 and LMP2 are bidirectionally transcribed and
class I MHC genes (Nelson et al., 1993; Lim and Hui, share a promoter of 593 bp (Wright et al., 1995). We
1994; Reis et al., 1992), and the VCAM-1 gene (Neish et have previously defined the transcriptional start sites
al., 1995). IRF-1 is also associated with antiviral activity of TAP1 and LMP2 and, using a bidirectional reporter
(Matsuyama et al., 1993; MacDonald et al., 1990; Pine, construct, have characterized the basal promoter of
1992; Kimura et al., 1994) and may be at least partially both genes (Wright et al., 1995). In this study, the mecha-
responsible for the antiviral and antiproliferative effect nism of IFNg up-regulation of TAP1 and LMP2 is investi-
of IFNg (Kirchhoff et al., 1993). Results obtained with gated. An element at 2186 to 2200 relative to the TAP1
IRF-1-deficient mice support these observations. IRF- translational start site was previously identified by se-
12/2 mice infected with encephalomyocarditis virus quence homology to other IFN-responsive elements
(EMCV) display increased mortality (Kimura et al., 1994); (Yang et al., 1992; Beck et al., 1992). Our site analysis
susceptibility to infection with Mycobacterium bovis is shows that this shares significant homology to an IRF-1
also increased in these mice (Kamijo et al., 1994). These target site and will henceforth be referred to as an IRF-E.
results confirm an important role for IRF-1 in the re- In vivo genomic footprinting was used to investigate
sponse to specific viral and intracellular bacterial infec- protein–DNA contacts at this site and thereby establish
tions. The molecular mechanism through which IRF-1 the physiologic relevance of this site to IFNg induction.
mediates these effects has yet to be established. A summary of the contacts is shown in Figure 1A. Some
Analysis of IRF-1-deficient mice has revealed some weak contacts are visible prior to IFNg treatment (Figure
unexpected results, including a normal level of IFNb 1A, arrows without stars). IFNg treatment for 5 or 18 hr
expression and, most pertinent to this study, a dramatic induces significant additional DNA contacts at the IRF-E
decrease in the number of CD81 T cells (Reis et al., site (2186 to 2200) (Figures 1A and 1B, starred arrows
1994; Matsuyama et al., 1993). A significant reduction indicate IFNg-induced changes). Strong protections are
of CD42CD81 cells was observed in the peripheral blood, induced on the lower strand at 2187, 2194, and 2200
lymph nodes, spleens, and thymi of these mice. There is
(Figures 1A and 1B, open starred arrows with long tails),
mounting evidence that positive selection occurs when
as well as three weaker induced protections at 2186,
immature CD3lo1CD41CD81 thymocytes with appro-
2196, and 2197 (open starred arrows with short tails).
priate T cell receptors (TCRs) interact with self-MHC
In addition, a very strong guanine enhancement (2192,molecules expressed on thymic epithelial cells and as
closed arrow with long tail) and a weak adenine en-a result are rescued from apoptosis (Lo and Sprent,
hancement are also induced (2195, closed arrow with1986; Fink and Bevan, 1978; Zinkernagel and Doherty,
short tail). All of the IFNg-induced contacts on the lower1974). TCR binding to an MHC class I molecule generally
strand occur within the IRF-E homology domain. On theleads to differentiation into a CD42CD81 T cell, while
upper strand, only one IFNg-induced hypersensitive siteTCR binding to a class II molecule leadsto differentiation
is detected (2205, starred closed arrow), while anotherinto a CD41CD82 T cell (Teh et al., 1988). Negative selec-
contact at 2217 (closed arrow) is not IFNg induced.tion also involves immature thymocytes and eliminates
The former contact occurs at the first guanine residuepotentially autoreactive cells with excess affinity for
flanking the 59 side of the IRF-E motif. Interestingly, inMHC molecules (Hugo et al., 1993; Schwartz, 1989).
vivo protein–DNA interactions at the downstream NF-Engagement of a class I MHC molecule is required for
kB and GC motifs described previously did not changeefficient differentiation and maturation of CD81 T cells
upon IFNg treatment, indicating that the changes in-(von Boehmer et al., 1993). Peptide must be present in
duced by IFNg are specific for the IRF-E site (Figure 1C)the binding cleft of the class I molecule for the latter to
(Wright et al., 1995). These results confirm that, uponbe expressed stably on the cell surface (Schumacher et
induction with IFNg, protein–DNA contacts at the IRF-Eal., 1990; Townsend et al., 1990), and data suggest that
are specifically altered in vivo, revealing that a change inthe actual identity of the bound peptide may be impor-
tant for positive selection (Ashton-Rickardt, 1993). IRF-E protein binding is induced by cytokine treatment.
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Figure 1. Altered Protein–DNA Contacts at
the IRF-E Following IFNg Treatment
(A) A summary of the in vivo footprint results
showing the IRF-E site (stippled) and the in
vivo contact points.
(B) Genomic footprinting was performed on
deproteinized DNA in vitro (lanes 1 and 5),
DNA from untreated HeLa cells (lanes 2 and
6), or HeLa cells treated with 250 U/ml of IFNg
for 5 hr (lanes 3 and 7) or 18 hr (lanes 4 and
8). The left panel shows contacts on the lower
strand, and the right panel shows contacts
on the upper strand. The location of the IRF-E
site is bracketed to the left of each panel.
Protections are indicated by open arrow
heads, with weaker protections represented
by shortened tails. Enhancements are repre-
sented by closed arrowheads, with weak en-
hancements represented by shorter tails.
Protections or enhancements specifically in-
duced by IFNg are additionally labeled with
a star.
(C) Contacts at the downstream NF-kB and
GC box are shown and are not altered after
IFNg treatment. Lanes 1–4 use the same DNA
samples as shown in lanes 1–4 of (B).
The IRF-E Is Essential for IFNg Induction eliminates LMP2 induction. This result implicates se-
quences in this region in the up-regulation of LMP2. Site-of TAP1 and LMP2
specific mutation was performed to evaluate specificallyTo determine whether the IRF-E element is required for
the function of the IRF-E site. Mutation of this site com-the response of TAP1 and LMP2 to IFNg, we used a
pletely eliminates IFNg induction of both TAP1 andbidirectional reporter system consisting of the 593 bp
LMP2 (Figures2A and 2C, mtIRF-E). Therefore, the IRF-ETAP1/LMP2 promoter flanked by two divergently ori-
is essential for both TAP1 and LMP2 up-regulation byented reporter genes, human growth hormone (HGH)
IFNg.and chloramphenicol acetyltransferase (CAT) (Wright et
al., 1995). This construct, L-HGH/T-CAT, allows the si-
The IRF-E Site Can Confer IFNg Inducibilitymultaneous analysis of transcriptional activity in both
To address the functional role of the IRF-E motif in IFNgdirections (Figure 2A). HGH is secreted into the superna-
induction, we tested the ability of the IRF-E to confertant and analyzed by radioimmunoassay, and CAT activ-
function to a heterologous promoter. A single copy of
ity isdetermined by standard thin-layer chromatography
the TAP1/LMP2 IRF-E motif was inserted 59 to the heter-
of cell extracts. IFNg induction of HeLa cells up-regu-
ologous thymidine kinase minimal promoter linked to
lates LMP2 by 21.9-fold and TAP1 by 6.7-fold (Figure the HGH reporter gene. When transfected into HeLa
2B). LMP2 appears in this assay to be more strongly cells, the presence of a single IRF-E site confers a 6.3-
induced by IFNg; however, it is difficult to draw any fold induction upon treatment with 250 U/ml of IFNg
conclusions from this because the posttranscriptional (Figure 3, IRF-E) compared with a minimal IFNg induc-
effects of IFNg on the reporter proteins (CAT and HGH) tion of the minimal promoter (Figure 3, pTKGH). The
have not been systematically compared. Nonetheless, ability to confer responsiveness is orientation indepen-
this does not compromise the finding that both TAP1 dent, since this site can also mediate induction when
and LMP2 expression are strongly induced by IFNg. cloned in the opposite orientation (Figure 3, revIRF-E,
Deletion of the TAP1-proximal region that includes the 7.3-fold induction). Mutating the IRF-E site in these con-
structs abolishes IFNg induction (Figure 3, mtIRF-E andIRF-E (Figures 2A and 2C, p593-207LMP) essentially
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Figure 3. IRF-E Site Can Confer IFNg Inducibility to a Heterologous
Promoter
The IRF-E and revIRF-E constructs contain one copy of the TAP1/
LMP2 IRF-E cloned upstream of the minimal HSV–TK promoter in
opposite orientations. The mtIRF-E and mtrevIRF-E constructs have
a mutated IRF-E site. The construct pTKGH only contains the
HSV–TK promoter. Induced samples were treated with 250 U/ml of
IFNg for 24 hr. Fold induction was determined by dividing the in-
duced HGH result by the uninduced value. Results shown are the
average of three experiments, with the error bars representing
the SEM.
The IRF-1 Protein Binds to the IRF-E Motif
To identify and characterize the proteins that bind to
the IRF-E site, we used in vitro gel mobility shift assays
and supershifts. Nuclear extracts were isolated from
HeLa cells treated with 250 U/ml of IFNg for 5 hr and
incubated with a probe spanning the IRF-E site. Two
inducible protein–DNA complexes bind to the IRF-E (Fig-
ure 4A, lane 1 versus lane 2, arrow and star). No addi-
tional complexes were observed when using extracts
from HeLa cells treated with IFNg for 12 hr (data not
shown). These inducible complexes were specific, since
a 100-fold excess of homologous cold competitor com-
pletely eliminated binding to the probe (Figure 4A, lane
3). An oligonucleotide containing mutations identical to
Figure 2. Deletion of the TAP-Proximal Promoter and Disruption of those used in the mtIRF-E constructs in Figure 2A did
the IRF-E Abrogates IFNg Inducibility not compete the faster migrating complex, but did com-
(A) A schematic diagram of the constructs used below. Also see pete the slower complex, suggesting that the latter in-
Experimental Procedures.
volves sequences outside of the IRF-E site (Figure 4A,(B) IFNg induces both TAP1 and LMP2. Data shown are the average
lane 4, arrow and star).of three experiments with SEM. Fold induction is determined by
We further studied the identity of the lower complexdividing the IFN-induced result by the uninduced value.
(C) Deletion of the TAP-proximal region that includes the IRF-E site using a panel of cold competitors containing various
(p593-207LMP) eliminates LMP2 induction (top graph). Site-specific known IFN-regulatory cis-acting sites. An oligonucleo-
mutation of the IRF-E site (mtIRF-E) also eliminates IFNg induction tide containing a consensus ISRE site did compete the
of TAP1 and LMP2 (top and bottom graphs). Results of the deletion
complex (Figure 4A, lane 5). The ISRE site is known toand mutation are the average of the fold induction of three and four
bind both the ISGF-3 complex and the IRF-1 proteinexperiments, respectively, with the error bars representing the SEM.
(Pine et al., 1990; Levy et al., 1988; Tanaka et al., 1993;Induced samples were treated with 250 U/ml of IFNg for 24 hr. Fold
induction is calculated by dividing the IFN-induced value by the Harada et al., 1989); however, the ISGF-3-binding site
uninduced result. is longer than the IRF-1-binding site. The IRF-E identified
here contains homology to both the longer ISRE motif
and a shorter IRF-E. The ISGF-3 complex predominantly
mediates up-regulation of genes by IFNa and is lessmtrevIRF-E). Therefore, the IRF-E site is clearly a cis-
acting element that functions independently of direction likely to be involved here (Stark and Kerr, 1992; Schindler
and Darnell, 1995). The involvement of ISGF-3 bindingand does not require the presence of additional TAP1/
LMP2 promoter elements to mediate IFNg respon- to the TAP1/LMP2 site was also excluded by serological
analysis (see below). Oligonucleotides containing asiveness.
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Figure 4. IFNg Induces a Cycloheximide-
Sensitive Complex That Binds to the IRF-E
(A) Gel shift analysis indicates that one pro-
tein complex is induced with IFNg (arrow, lane
1 versus lane 2). The arrow indicates the posi-
tion of the induced complex. A second upper
complex (star) is induced, but is not specific
for the IRF-E motif (lanes 3 and 4). Nuclear
extracts were from HeLa cells induced with
250U/ml of IFNg for 5 hr (IFNg) anduninduced
cells (UNT). The probe spans the TAP1/LMP2
IRF-E site with 11 bp of flanking sequence.
Oligonucleotide competitors are designated
in the top row (1003) and are used at 100-fold
molar excess. WT, homologous cold IRF-E
competitor; MT, cold competitor with a mu-
tated IRF-E site. NUC. EX., nuclear extract.
(B) Incubation with the anti-IRF-1 antibody
induces a shifted complex (stars) and re-
duces the formation of the inducible complex
(arrow). Antibodies are indicated at the top.
AB, antibody.
(C) Pretreatment with cycloheximide inhibits
in vitro formation of the inducible complex
(arrow). Cold competitors are indicated at the
top using the same abbreviations as in (A)
and are used at 100-fold molar excess. IFNg
indicates treatment with 250 U/ml of IFNg
alone for 5 hr; CHX/IFNg indicates treatment
with cycloheximide 15 min prior to treatment
with 250 U/ml of IFNg for 5 hr.
(D) Pretreatment with cycloheximide inhibits
IFNg-induced in vivo binding at the IRF-E.
Genomic footprinting was performed on in
vitro deproteinized DNA (lane 1), DNA from
untreated HeLa cells (lane 2), HeLa cells
treated with 250 U/ml of IFNg for 2 hr (lane
3), HeLa cells treated with 50 mg/ml of cyclo-
heximide alone (lane 4), or HeLa cells pre-
treated with 50 mg/ml of cycloheximide prior
to the addition of 250 U/ml of IFNg for 2 hr
(lane 5). Markings are as described in Fig-
ure 1.
palindromic IFN-response element (pIRE) site (Figure addition of probe resulted in a shifted complex (Figure
4B, stars) and a reduction of the original complex (lane4A, lane 6) or an IFNg-activated site (GAS) (lane 7), two
cis-acting elements bound by STAT1 complexes, did 1 versus lane 2). The IFN-induced complex undergoes
a significant shift, indicating that IRF-1 is a componentnot compete the complex (Harroch et al., 1994; Pine et
al., 1990; Levy et al., 1988). The lack of competition with of the complex. However, since the shift is only partial,
the complex may also include proteins in addition tothese sites implies that STAT1 (signal transducer and
activator of transcription 1) homodimers do not bind to IRF-1. Anti-IRF-2 antisera did not affect the complex
(Figure 4B, lane 3). Irrelevant antisera to the NF-kB sub-the TAP1/LMP2 IRF-E site. In contrast, an oligonucleo-
tide containing a consensus IRF-binding site does com- unit p52 had no effect (Figure 4B, lane 4). The addition
of IRF-1 antisera did not affect the DNA probe in thepete the complex (Figure 4A, lane 8). This site has been
demonstrated to bind the IRF-1 with high affinity (Mac- absence of extract (data not shown). Antisera to
STAT1a/b, STAT2, or STAT3 did not prevent binding ofDonald et al., 1990) and does not bind the ISGF-3 com-
plex, which requires a longer target sequence for DNA the complex to the probe (data not shown). Control
experiments using a canonical ISRE element confirmedbinding (Tanaka et al., 1993). When mutations known
to abolish IRF-1 binding are introduced, competition is the ability of the anti-STAT antibodies to supershift their
respective proteins properly (data not shown). Theseeliminated (Figure 4A, lane 9). These results suggest that
the inducible protein complex binding to the IRF-E may results directlyconfirm that IRF-1 is present in the induc-
ible complex.be the IRF-1 or the IRF-2 protein (or both).
Since IRF-1 and IRF-2 proteins recognize the same To verify further the presence of IRF-1 in this complex,
we utilized the requirement of protein synthesis for ex-cis-acting element and ISGF-3 recognizes a similar ele-
ment, additional experiments are required to determine pression of IRF-1. Induction of IRF-1 DNA binding activ-
ity requires protein synthesis, while IRF-2 is a constitu-the identity of the protein factor that binds to this site.
Antibody supershift experiments were employed to con- tive factor (Levy et al., 1988; Pine et al., 1990). Likewise,
the STAT proteins do not requireprotein synthesis, sincefirm further the identity of protein in the complex. Addi-
tion of anti-IRF-1 antisera to the extracts prior to the they reside inactive in the cytoplasm (Stark and Kerr,
Immunity
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Figure 5. TAP1 and LMP2 Expression Is Re-
duced in the IRF-12/2 Mice
(A) Northern blot analysis using 20 mg of total
RNA extracted from the spleen of an IRF-12/2
mouse and a wild-type mouse. The GAPDH
control is shown below.
(B) Lanes 1 and 2, thymic RNA from two IRF-
12/2 mice; lanes 3 and 4, thymic RNA from
wild-type mice; lanes 5 and 6, thymic RNA
from mice heterozygous for the IRF-1 allele.
We loaded 25 mg of total RNA. All mice were
4 weeks of age. The cyclophilin control for
loading is shown at the bottom.
1992; Schindler and Darnell, 1995; Sen and Ransohoff, 2). In the thymus of 4-week-old IRF-12/2 mice, TAP1
expression is significantly reduced compared with wild-1993). If the inducible complex contains IRF-1, inhibition
of protein synthesis should prevent binding of the pro- type (Figure 5B, lanes 1 and 2 versus lanes 3 and 4) and
heterozygote mice (lanes 5 and 6). LMP2 expression istein complex to the IRF-E site following treatment with
IFNg. Nuclear extracts were prepared from HeLa cells reduced compared with wild-type levels, although the
LMP2 expression is low overall. This result demon-treated for 15 min with cycloheximide prior to the addi-
tion of IFNg. Cycloheximide treatment eliminates bind- strates that IRF-1 is critical for the expression of both
TAP1 and LMP2 in vivo.ing of the inducible complex (Figure 4C, arrow) to the
IRF-E probe (lane 1 versus lane 4). This result confirms It is interesting that a deficiency of IRF-1 results in a
greatly reduced TAP1 and LMP2 basal expression levelthat in extracts from cells treated for 5 hr with IFNg,
binding of the inducible complex requires protein syn- in vivo. It is likely that the milieu in which lymphocytes
reside in vivo has a basal level of IFN and other cyto-thesis. An upper complex is formed in cycloheximide-
treated cells, but it appears to be nonspecific (Figure kines, such that in vitro tissue culture conditions do not
duplicate the in vivo conditions. In fact, a previous study4C, lanes 5 and 6). This result is consistent with the
IRF-1 protein binding to the IRF-E site in vitro. has demonstrated the presence of a constitutive level
of IRF-1 in organs of untreated wild-type mice (Reis etTo confirm the in vivo significance of this binding, we
utilized in vivo genomic footprinting to examine binding al., 1994). Another curious observation is that when IRF-
12/2 mice are injected with IFNg, an up-regulation ofat the IRF-E site after cycloheximide treatment of intact
cells. Binding at the IRF-E is strongly induced after 2 TAP1 and LMP2 expression is observed (data not
shown). This result suggests the presence of redun-hr of IFNg treatment (Figure 4D, lane 3 versus lane 2).
Treatment with cycloheximide for 15 min prior to the 2 dancy in the IFNg response of TAP1 and LMP2 and that
additional elements, perhaps not examined in the inhr IFNg treatment completely abolishes binding to the
IRF-E (Figure 4D, lane 5 versus lane 3). Therefore, bind- vitro promoter analysis, are functional in vivo. Another
alternative includes the usage of the IRF-E site by othering at the IRF-E in vivo requires protein synthesis. This
result is consistent with IRF-1 binding at the IRF-E in proteins in the absence of IRF-1, although no residual
binding at the IRF-E site was observed in cycloheximide-vivo and mediating the up-regulation of TAP1 and LMP2
by IFNg. treated cells (Figure 4D).
Expression of LMP2 and TAP1 Are Reduced
in IRF-12/2 Mice CD81 T Cells and Class I MHC Are Reduced
in IRF-12/2 MiceTo address the in vivo relevance of IRF-1-mediated reg-
ulation of TAP1 and LMP2, we studied IRF-1-deficient A previous report using IRF-12/2 mice generated from
another laboratory has shown reduced CD81 T cells inmice (Reis et al., 1994). Total RNA extracted from IRF-
12/2 and wild-type mouse organswas analyzed by North- IRF-1-deficient mice (Matsuyama et al., 1993). To con-
firm these studies and extend them to the strain of IRF-ern blot analysis. In the IRF-12/2 mice, TAP1 and LMP2
expression is significantly reduced in the spleen com- 1-deficient mice used here, we performed three-color
flow cytometric analysis of thymocytes for CD4, CD8,pared with wild-type mice (Figure 5A, lane 1 versus lane
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Table 1. Class I MHC Surface Expression Is Lowered on IRF-12/2
Thymocyte Subsets
Percentage of Class I Mean
Total Thymocytes Fluorescence Intensity
Thymocyte
Subpopulation 2/2 1/1 2/2 1/1
CD42/CD82 1.63 3.85 126.34 387.28
CD42/CD81 1.95 4.98 143.08 353.93
CD41/CD81 76.62 77.72 19.95 41.53
CD41/CD82 19.81 13.46 157.19 255.72
Figure 6. Class I MHC mRNA Levels Are Normal in the IRF-12/2 Mice
Thymocytes from IRF-12/2 and IRF-11/1 mice were analyzed for MHC
Class I MHC levels were analyzed using RT–PCR. Thymic mRNA
class I surface expression by three-color flow cytometry. Thymo- isolated from IRF-12/2 and IRF-11/1 mice were reverse transcribed
cytes were identified according to their forward- and side-scatter into cDNAs. The cDNAs were amplified by RT–PCR using class
profile, and a total of 40,000 events were collected. Cells were I–specific (lane 1) or actin-specific primers (lane 2). C, control for
stained with antibodies directed against CD4, CD8, and class I DNA contamination. To ensure that the amplification reaction was
(H-2Kb/H-2Db). CD4/CD8 subsets were selected and analyzed for in the linear range, we performed a dilution. To ensure that the cDNA
class I expression. Background staining was detected with an irrele- was the only limiting factor, we used the lowest quantity of input
vant isotype control antibody and subtracted from corresponding
cDNA that yielded product.
test samples. Similar results were obtained in three separate experi-
ments and when using a second anti–MHC class I antibody (data
not shown).
Discussion
and class I surface expression (Table 1). In the IRF-1- This report shows that the IRF-1 protein binds to an
deficient thymus, the CD81 T cell population is reduced IRF-E site within the TAP1/LMP2 promoter region and
by 2.5-fold (1.95% compared with the wild-type level of that this site is physiologically important, as demon-
4.98%). These data confirm that these IRF-12/2 mice strated by the in vivo footprinting analysis. Disruption
display the previously described phenotype of an edu- of the IRF-1 gene in mice leads to low TAP1 and LMP2
cational defect in CD81 T cells. gene expression, an observation consistent with the
This previous report also noted that class I MHC anti- effect of the mutated IRF-E on induction of the genes
gens are not reduced in IRF-12/2 mice (Matsuyama et in transfection experiments. In this report, the data dem-
al., 1993). This is in contrast with our expectation, as a onstrate a clear link among TAP1, LMP2, and IRF-1 and
reduction in TAP1 is likely to reduce the number of sur- suggest several interesting implications.
face class I MHC molecules. To clarify this issue, we The first implication arises from a common phenotype
examined the level of class I MHC expression on cells observed among the TAP12/2, LMP22/2, and IRF-12/2
from IRF-1-deficient mice used in this study. Cells from mice. All three mice have dramatically lowered CD81 T
all four thymic T cell populations (CD41, CD81, CD42 cell populations. In the TAP12/2 mice such a defect is
CD82, and CD41CD81) exhibited greatly reduced class expected, since without TAP1, class I MHC is not pres-
I MHC levels (Table 1). Decreased class I MHC was ent on the cell surface and cannot influence the educa-
observed in two of our laboratories. This result shows tion of CD81 T cells. Likewise, in mice lacking the b2m
an overall reduction in class I surface expression; its gene, a similar defect is observed (Zijlstra et al., 1990).
reduction in all four subpopulations of thymocytes in The lack of CD81 T cells in the LMP22/2 mice can be
IRF-12/2 mice rules out the trivial explanation that the explained by the role of LMP2 in antigen processing. It
decrease in class I molecules is simply attributable to has been suggested that the population of peptides
the loss of the CD81 T cell population. produced by LMP2 may be essential for the efficient
Several studies suggest that IRF-1 may contribute to education of CD81 T cells in the thymus (Van Kaer et al.,
class I MHC gene expression (Lim and Hui, 1994; Nelson 1994). It has been demonstrated that LMP2 has specific
et al., 1993; Reis et al., 1992). To clarify whether the cleavage properties (Boes et al., 1994; Gaczynska et al.,
reduction in class I MHC surface expression on IRF-12/2 1993; Driscoll et al., 1993). Association of the LMP2 and
cells is due to a decrease in class I expression or to LMP7 subunits with the proteasome complex quantita-
an indirect effect of lowered TAP/LMP expression, we tively increases cleavage at hydrophobic and basic resi-
utilized reverse transcription–polymerase chain reaction dues, producing peptides with specific characteristics.
(RT–PCR) analysis. A comparison of thymic RNA from Therefore, this class of peptides with specific sequence
IRF-12/2 and wild-type mice demonstrates that class I characteristics generated by LMP2 may be essential for
mRNA expression in the IRF-12/2 mice is essentially nor- the optimal selection of CD81 T cells. This is consistent
mal (Figure 6). This result is consistent with previous with findings that the identity of peptide in the class I
data that MHC class I can be induced by either IFNa or cleft can influence T cell education (Ashton-Rickardt,
IFNg in IRF-12/2 mice (Reis et al., 1994), suggesting that 1993). In one such study, previously characterized pep-
an IRF-1-independent mechanism of class I MHC induc- tides were added to fetal thymic organ culture from
tion does exist. This result demonstrates that the reduc- TAP12/2 mice (Ashton-Rickardt, 1993). It was found that
tion in class I surface expression is not simply due to not all peptides bound by class I MHC resulted in posi-
reduced class I mRNA levels and is consistent with the tive selection. The authors concluded that the ability of
decrease in class I surface expression resulting from a peptide to select CD81 T cells positively is not entirely
due to the stabilization of class I MHC molecules, butlowered TAP1 and LMP2 expression in the IRF-12/2 mice.
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that the specific sequence of thepeptides may be impor- and LMP genes or proteins, respectively,may be general
mechanisms used to evade the immune system (Hill ettant. In another study using fetal thymic organ culture,
mixtures of exogenously added peptides selected CD81 al., 1995; Fruh et al., 1995; Rotem Yehudar et al., 1994;
Ehrlich, 1995). LMP2, while not essential for the presen-T cells more efficiently than a single peptide (Hogquist
et al., 1993). This result indicates that a complex mixture tation of all epitopes, is important for the presentation
of specific viral antigens, as demonstrated in LMP2-of peptides is required for positive selection. Therefore,
the type of peptides generated by LMP2-mediated pro- deficient mice.
The cycloheximide, oligonucleotide competition, andcessing may contribute to CD81 T cell selection.
In contrast with LMP22/2 and TAP12/2 mice, the paucity supershift data suggest the lack of STAT1 involvement
in the IFNg induction mediated through the IRF-E siteof CD81 T cells in IRF-12/2 mice is less expected. The
phenotype of our IRF-12/2 mice is consistent with previ- defined here. The possibility exists that STAT1 may initi-
ate up-regulation at earlier timepoints (less than 5 hr)ous results (Reis et al., 1994). However, no prior evi-
dence exists implicating IRF-1 in T cell education. The after IFNg treatment, although the cycloheximide data
argue against STAT involvement (Figures 4C and 4D).results from this study provide a logical explanation for
this phenotype: IRF-12/2 mice have reduced TAP1 and A second possibility is that STAT1 may mediate the IFNg
induction of TAP1 and LMP2 through other elementsLMP2, hence resulting in reduced CD81 T cells. We also
demonstrated a reduction in the surface expression of not examined in this report. However, TAP1 expression
remains significantly up-regulated at 48 hr after IFNgMHC class I molecules on three thymic populations in
IRF-12/2 mice. This decrease is not due to a reduction treatment (data not shown), an observation that sug-
gests that proteins activated at later times play an impor-in class I MHC mRNA, as we have confirmed that class
I mRNA levels are normal in IRF-12/2 mice. The decrease tant role in sustaining the IFNg up-regulation.
In conclusion, this study shows that LMP2 and TAP1in class IMHC surface levels observed here is consistent
with the reduced expression of TAP1 and LMP2 in the are coordinately regulated by the IRF-1 protein both in
vitro and in vivo. This report provides a logical basis toIRF-1-deficient mice. We propose that the decrease in
TAP1 and LMP2 expression in the thymus of the IRF-1- explain the antiviral activity attributed to IRF-1 and the
sequence of events through which IRF-1 leads to appro-deficient mice results in lowered class I MHC surface
expression or presentation in the thymus (or both) and priate CD81 T cell differentiation and development.
is responsible for the observed defect in the CD81 T cell
Experimental Procedurescompartment.
A low level of CD81 T cells remain in IRF-12/2 mice
Cell Lines and Constructsand may be attributed to a number of causes. First,
HeLa cells (CCL2; American Type Culture Collection, Rockville, MD)
TAP1 and LMP2 expression is lowered but not abolished were grown as previously described (Wright et al., 1995). The con-
in IRF-12/2 mice, and this is likely sufficient for the selec- struction of L-HGH/T-CAT has been described previously (Wright
et al., 1995). The mtIRF-E vector was constructed by performingsite-tion of some CD81 T cells. Second, LMP22/2 mice have
directedmutagenesis (Kunkel et al., 1987) of L-HGH/T-CAT using theonly a partial (49%) reduction in thymic CD81 T cells
oligonucleotide 59-CAGCCATTTAGGGGACAGGTAGATCGAAAGC(Van Kaer et al., 1994). Therefore, some CD81 T cell
GGCCGC-39 (mutations underlined). The deletion constructs haveselection can occur in the absence of LMP2. TAP12/2
been previously described (Wright et al., 1995), with p593-207LMP
and b2m2/2 mice both have a severe deficiency in the having the CAT reporter abolished and the HGH reporter intact.
CD81 population, but still produce some CD81 T cells Heterologous promoter constructs were constructed by cloning
double-stranded, annealed IRF-E oligonucleotides (sequence iden-(Van Kaer et al., 1992). Alternative pathways of peptide
tical to gel-shift oligonucleotide shown below) into the filled-inacquisition have been proposed and could mediate the
HindIII site of the pTKGH vector (Nichols Institute, San Juan Capis-selection and differentiation of this small group of CD81
trano, CA). This construction places the oligonucleotide just up-
T cells (Van Kaer et al., 1992). Future studieswill address stream of the herpes simplex virus–thymidine kinase (HSV–TK) pro-
whether the CD81 T cells present in the IRF-1-deficient moter. The integrity of the constructs was confirmed by DNA
mice are a specific subpopulation of T cells or whether sequence determination.
the CD8 defect in these mice is simply quantitative.
TransfectionA prominent characteristic of IRF-1 is its antimicrobial
All transfections were performed by the standard CaPO4 protocolactivity; IRF-1-deficient mice are more susceptible to
(Chen and Okayama, 1987) using 15 mg of DNA purified by Qiagen
infection with EMCV (Kimura et al., 1994) and the intra- columns (Qiagen, Chatsworth, CA). To minimize variability, we
cellular bacterium M. bovis (Kamijo et al., 1994). The pooled duplicate DNA precipitates and then added half to the in-
antimicrobial activity of IRF-1 is specific, as no augmen- duced plate and half to the uninduced plate. The medium was
changed 4 hr after the addition of DNA precipitate, and 250 U/mltation of vesicular stomatitis virus infection is observed
of IFNg (provided by Genentech, South San Francisco, CA) wasin the IRF-1-deficient mice. However, constitutive ex-
added to the induced sample. Aliquots of media and cell extractspression of IRF-1 in vitro induces a broad antiviral resis-
were harvested 24 hr later. Protein content of the cell extracts was
tance to RNA viruses from three families (Pine, 1992). determined using the Bradford assay (Bradford, 1976). Cell extracts
Although it is likely that another IRF-1-regulated gene, (30 mg) were assayed for CAT as previously described (Wright et
al., 1995) and quantitated by phosphoimaging (Molecular Dynamics,iNOS, may contribute to this antiviral activity, we pro-
Sunnyvale, CA). Quantitation of the HGH in media aliquots was donepose that TAP1 and LMP2 also play a prominent role
by the standard radioimmunoassay (Nichols Institute).in mediating the antimicrobial activity linked to IRF-1
(Martin et al., 1994; Kamijo et al., 1994). TAP1 and LMP2
Gel Shift Analysis
are important for the presentation of viral epitopes by Nuclear extracts were prepared by the method of Dignam et al.
class I MHC. In fact, a growing number of studies indi- (1983). IFNg-induced extracts were prepared from HeLa cells in-
duced with 250 U/ml of IFNg for 5 hr. Cycloheximide-treatedextractscate that viral down-regulation or inhibition of the TAP
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were prepared by treatment with 50 mg/ml cycloheximide for 15 min were performed at 48C for 30 min. Thymocytes were identified ac-
cording to their forward- and side-scatter profiles, and a total ofprior to the addition of IFNg for 5 hr. The IRF-E oligonucleotide
probe is as follows: 59-GCGGCCGCTTTCGATTTCGCTTTCCCCTAA 40,000 events were collected using a Becton Dickinson FACScan
(San Jose, CA) flow cytometer. Individual CD4/CD8 subsets wereATGGCTG- 39. The oligonucleotides used for cold competitors are
as follows: mtIRF-E, 59-GCGGCCGCTTTCGATCTACCTGTCCCCTA selected and analyzed for class I expression with the Cicero soft-
ware program (Cytomation, Fort Collins, CO).AATGG CTG-39 (Reid et al., 1989; Blanar et al., 1989); pIRE, 59-CTG
ATTTCCCCGAAATGACGG-39 (Harroch et al., 1994); conISRE,
59-GGCTTCAGTTTCGGTTTCCCTTTCCCGAGGATC-39 (Veals et al., RT–PCR Analysis
RT–PCR analysis was performed essentially as previously described1992); GAS, 59-CATGTTATGCATATTCCTGTAAGTGCATG-39 (Khan
et al., 1993); conIRF, 59-GCTTTCGCTTTCGCTTTCGCTTTC-39 (Par- (Chin et al., 1994). Input cDNA was titrated to the lowest possible
amount that yielded amplification in order to ensure that the reactionrington et al., 1993; MacDonald et al., 1990); and mtconIRF,
59-CATTTCCATTTCCATTTCCATTTC-39 (Parrington et al., 1993; would be in the linear range. The procedure is briefly described
here. Thymic RNA (15 mg, prepared as described above) was pre-MacDonald et al., 1990). Antibodies were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA). The IRF-1 antibody (C-20; treated with 15 U of RNase-free DNase I for 30 min at 378C(Promega,
Madison, WI). The RNA was reverse transcribed, with one sampleSanta Cruz Biotechnology) is an affinity-purified rabbit polyclonal
antibody raised against a peptide representing amino acids 306–325 lacking DNA as a control. First strand cDNA was synthesized with
1.5 mg of random hexamer (GIBCO BRL, Grand Island, NY) and inof the carboxyl terminus. This antisera is not cross-reactive with
either IRF-2 or ISGF-3g p48. Control extracts for conISRE gel shifts the presence of 10 mM DTT, 1.25 mM of each dNTP, and 1200
U of M-MLV reverse transcriptase (GIBCO BRL). Quantitation waswere prepared as previously described (Veals et al., 1992) by treat-
ment with 500 U/ml of IFNg for 17 hr and with 500 U/ml of IFNa for performed by using 1 ml of cDNA synthesized as above, 1.6 U of
Taq DNA polymerase (GIBCO BRL), 2.5 mM of each dNTP, and1 hr. Gel shift analysis was performed as previously described
(Wright et al., 1995). primer in a total volume of 20 ml. We used 20 pmol of primers specific
for mouse H-2Dk and H-2Db for 25 cycles of amplification of class
I cDNA (primer 1, 59-ACCCAGAACAGCAACGATCAC-39; primer 2,Mice
59-CCCTGACCTGGCAGTTGAATG-39), which produce a 269 bpConstruction of the transgenic IRF-12/2 mice has been previously
product. We used 15 pmol of the following primers for 25 cyclesdescribed (Reis et al., 1994). The mice used here were subsequently
of amplification of actin, used as a loading control: primer 1,bred to siblings to achieve a pure background. Genotype of the
59-CCTTCCTGGGCATGGGAGTCCT-39; primer 2, 59-GGAGCAATGAIRF-12/2 mice was confirmed by Southern blot analysis (Sambrook
TCTTGATCTTC-39; these produce a 200 bp product. We loaded 9et al., 1989). Mice were housed under specific pathogen–free condi-
ml of each reaction onto a 2% agarose gel and stained with ethidiumtions.
bromide for visualization.
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